DNDI-6148: A Novel
Benzoxaborole Preclinical Candidate
for the Treatment of Visceral Leishmaniasis
Posted on 2021-10-29 - 06:04
Visceral leishmaniasis
(VL) is a parasitic disease endemic across
multiple regions of the world and is fatal if untreated. Current therapies
are unsuitable, and there is an urgent need for safe, short-course,
and low-cost oral treatments to combat this neglected disease. The
benzoxaborole chemotype has previously delivered clinical candidates
for the treatment of other parasitic diseases. Here, we describe the
development and optimization of this series, leading to the identification
of compounds with potent in vitro and in
vivo antileishmanial activity. The lead compound (DNDI-6148)
combines impressive in vivo efficacy (>98% reduction
in parasite burden) with pharmaceutical properties suitable for onward
development and an acceptable safety profile. Detailed mode of action
studies confirm that DNDI-6148 acts principally through the inhibition
of Leishmania cleavage and polyadenylation specificity
factor (CPSF3) endonuclease. As a result of these studies and its
promising profile, DNDI-6148 has been declared a preclinical candidate
for the treatment of VL.
CITE THIS COLLECTION
DataCiteDataCite
3 Biotech3 Biotech
3D Printing in Medicine3D Printing in Medicine
3D Research3D Research
3D-Printed Materials and Systems3D-Printed Materials and Systems
4OR4OR
AAPG BulletinAAPG Bulletin
AAPS OpenAAPS Open
AAPS PharmSciTechAAPS PharmSciTech
Abhandlungen aus dem Mathematischen Seminar der Universität HamburgAbhandlungen aus dem Mathematischen Seminar der Universität Hamburg
ABI Technik (German)ABI Technik (German)
Academic MedicineAcademic Medicine
Academic PediatricsAcademic Pediatrics
Academic PsychiatryAcademic Psychiatry
Academic QuestionsAcademic Questions
Academy of Management DiscoveriesAcademy of Management Discoveries
Academy of Management JournalAcademy of Management Journal
Academy of Management Learning and EducationAcademy of Management Learning and Education
Academy of Management PerspectivesAcademy of Management Perspectives
Academy of Management ProceedingsAcademy of Management Proceedings
Academy of Management ReviewAcademy of Management Review
Mowbray, Charles E.; Braillard, Stéphanie; Glossop, Paul A.; Whitlock, Gavin A.; Jacobs, Robert T.; Speake, Jason; et al. (2021). DNDI-6148: A Novel
Benzoxaborole Preclinical Candidate
for the Treatment of Visceral Leishmaniasis. ACS Publications. Collection. https://doi.org/10.1021/acs.jmedchem.1c01437